51-OR: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BI 456906 in People with Overweight/Obesity
Year: 2023
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Diabetes
DOI: 10.2337/db23-51-or
Institution: Boehringer Ingelheim (Canada)
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4381734495
